Abcl stock forecast.

Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 20.50, with a high estimate of 34.00 and a low estimate of 10.00. The median estimate represents a +323.99% increase from the last price of 4.84.ALK Stock 12 Months Forecast. $51.25. (62.03% Upside) Based on 12 Wall Street analysts offering 12 month price targets for Alaska Air in the last 3 months. The average price target is $51.25 with a high forecast of $70.00 and a low forecast of $41.00. The average price target represents a 62.03% change from the last price of $31.63.AbCellera Biologics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 27,470,000 shares, a drop of 1.2% from the previous total of 27,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...Nov 16, 2023 · Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.

Find the latest AbCellera (NASDAQ: ABCL) stock information.

AbCellera ( NASDAQ: ABCL) listed on the Nasdaq in December 2020, completing a monstrous initial public offering of 24.15m shares at a price of $20 per share, for funds of ~$483m, which would be ...

VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.Bitfarms Ltd () Stock Market info Recommendations: Buy or sell Bitfarms stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bitfarms share forecasts, stock quote and buy / sell signals below.According to present data Bitfarms's BITF shares and potentially its market environment have been in a bullish cycle in the …Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors According to our current ABC stock forecast, the value of AmerisourceBergen shares will rise by 0.00% and reach $ 179.98 per share by November 22, 2023. According to our technical indicators, the current …Nov 16, 2023 · Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector.

Disclaimer: While every effort will be made to ensure that Bureau of Meteorology radar imagery is available on these web pages, there may be occasions when equipment or communications failure make this impossible. The Bureau's ability to restore the radar display following an outage may be limited by the priority to maintain forecasting and …

16:00 EST ABCL Stock Quote Delayed 30 Minutes ... ABCL Stock Predictions, Articles, and Abcellera Biologics Inc News From InvestorPlace From the Web 7 Best Stocks Under $10 to Buy in April ...

Based on analysts projections #ABCL is expected to experience a positive growth trajectory over the next year. The current average ABCL price target, as estimated by these analysts, is $27.75.. The predictions for the future ABCL stock price range from a low of $18.00 to a high of $34.00, highlighting the variability of market expectations for ABCL.Find the latest Institutional Holdings data for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.An XYZ stock analysis is the complement to an ABC analysis, and adds a layer of statistical review that shows the standard deviation of usage. ... Based on these classifications, companies can use the demand forecast and XYZ material classification to determine optimal order schedules.

AB Capital Share Price: Find the latest news on AB Capital Stock Price. Get all the information on AB Capital with historic price charts for NSE / BSE.Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.ABCL Forecast 2023. Check the latest forecasts. Read charts, analyst ratings, dividend and earningsFuture criteria checks 2/6. AbCellera Biologics's earnings are forecast to decline at 12.1% per annum while its annual revenue is expected to grow at 23.9% per …Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.

ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million.

According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecastsVANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 29, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 20.50, with a high estimate of 34.00 and a low estimate of 10.00. The median estimate represents a +323.99% increase from the last price of 4.84.ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.May 4, 2023 at 2:15 PM · 3 min read. AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to ...View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

ABCELLERA BIOLOGICS share price in real-time (A2QKXS / CA00288U1066), charts and analyses, news, key data, turnovers, company data.

Nov 25, 2023 · At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87.

52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.AbCellera Biologics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 27,470,000 shares, a drop of 1.2% from the previous total of 27,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Coupang stock is Moderate Buy based on the current 2 hold ratings and 2 buy ratings for CPNG. The average twelve-month price prediction for Coupang is $22.50 with a high price target of $25.00 and a low price target of $20.00.ABCELLERA BIOLOGICS share price in real-time (A2QKXS / CA00288U1066), charts and analyses, news, key data, turnovers, company data.Nov 25, 2023 · At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87. Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of AbCellera Biologics The definition of company insiders can be subjective and does ...Dec 1, 2023 · According to 16 stock analysts, the average 12-month stock price forecast for SOFI stock stock is $8.78, which predicts an increase of 12.13%. The lowest target is $3.00 and the highest is $15. On average, analysts rate SOFI stock stock as a hold. Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) ... Quite a few analysts cover the stock, so you could look into forecast growth quite easily.At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87.AbCellera Biologics Stock Chart and Share Price Forecast, Short-Term "ABCL" Stock Prediction for Next Days and Weeks Walletinvestor.com AbCellera Biologics Inc (ABCL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 AbCellera Biologics is no different. Shares of this biotech have climbed 6.9% year over year as of close on January 16. The stock has shot up 9.3% in the first weeks of the new year. This biotech stock went public on the NASDAQ on December 11, 2020. It would suffer a steady decline in the months that followed its initial public offering (IPO).

The current average ABCL price target, as estimated by these analysts, is $27.75. The predictions for the future ABCL stock price range from a low of $18.00 to a high of $34.00 , highlighting the variability of market expectations for ABCL . View live AbCellera Biologics Inc. chart to track its stock's price ... View live AbCellera Biologics Inc. chart to track its stock's price action. Find market predictions, ABCL financials and market ... Market closed Market closed. No trades. See on Supercharts. Overview . News Ideas Financials Technicals Forecast . ABCL chart. Today 1.06% 5 ...ABCL Stock Performance on October 13, 2023: Overview, Analysis, and Projections. ABCL Stock Performance on October 13, 2023: – Previous close on October 12, 2023: $4.39 – Opening price on October 13, 2023: $4.41 – Range of fluctuation: $3.92 to $4.41 – Trading volume on October 13, 2023: 4,206,194 sharesABCL Stock Forecast - Is ABCL a buy or sell? Find out now with a free analysis on AbCellera Biologics. Should I buy or sell ABCL? ABCL Stock Analysis - [Full Report] ABCL Chart by TradingView. Antibodies Stocks Antibody Stocks Biologics Stocks Database Stocks Drug Stocks Immune Stocks Natural StocksInstagram:https://instagram. sandp 500 index funds listipos this monthbest supplemental prescription insurancebuy carvana stock ABCL | AI Stock Analysis for AbCellera Biologics Inc ABCL Including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and More. Start now …Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply. It has been approved by the TGA as a diabetes treatment but is being prescribed ... masterworks io reviewdemo trading simulator The current average ABCL price target, as estimated by these analysts, is $27.75. The predictions for the future ABCL stock price range from a low of $18.00 to a high of $34.00 , highlighting the variability of market expectations for ABCL . low priced stocks to buy now Nov 24, 2023 · On a fall, the stock will find some support from the long-term average at approximately $4.30. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Friday, October 27, 2023, and so far it has risen 13.30%. Dec 1, 2023 · ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million.